Annovis Bio Achieves $6 Million Funding Milestone
Annovis Bio, Inc. (NYSE: ANVS), a pioneer in developing innovative therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's, has successfully closed its previously announced registered direct offering of common stock. This strategic financial maneuver netted the company approximately $6 million, which will be directed towards enhancing its research efforts and operational capacity.
Details of the Offering
In this offering, Annovis aimed to provide investors with 4,000,000 shares of common stock at a purchase price of $1.50 per share, alongside pre-funded warrants as an alternative. The prominent investment bank H.C. Wainwright & Co. was appointed as the exclusive placement agent, demonstrating confidence in the company's growth potential and mission.
Use of Proceeds
The funds raised through this offering will primarily support working capital and general corporate purposes. Annovis is committed to advancing its research and development initiatives, making significant strides in addressing the challenges posed by neurodegenerative diseases. This commitment is reflected in the company’s pursuit of therapies that could dramatically improve patient outcomes.
Commitment to Innovative Therapeutics
Annovis Bio's approach centers around the development of transformative therapies that could offer new hope to those affected by debilitating conditions like Alzheimer's and Parkinson's disease. The company has been steadfast in its mission to enhance patient quality of life through innovative solutions that target the underlying causes of these neurodegenerative disorders.
About Annovis
Established with a vision to tackle the realities of neurodegeneration, Annovis Bio operates from Malvern, Pennsylvania. The company is steadfast in its dedication to addressing the unmet needs in the therapeutic landscape for neurodegenerative diseases. By leveraging novel scientific discoveries, Annovis is well-positioned to innovate and expand its therapeutic options to better serve patients.
Company Information and Contact
For more details about Annovis Bio and its advancements in neurodegenerative treatments, visit their official website. The company encourages inquiries and has provided contact information for interested parties.
Frequently Asked Questions
What is the main goal of Annovis Bio?
Annovis Bio aims to develop innovative therapies for neurodegenerative diseases such as Alzheimer’s and Parkinson’s to improve patient outcomes.
How much capital did Annovis raise through the offering?
The company successfully raised $6 million through its registered direct offering.
Who acted as the placement agent for this offering?
H.C. Wainwright & Co. served as the exclusive placement agent for this capital raising initiative.
What will the proceeds from the offering be used for?
The net proceeds will be allocated toward working capital and general corporate purposes, supporting the company’s research initiatives.
Where is Annovis Bio headquartered?
Annovis Bio is headquartered in Malvern, Pennsylvania, focusing on innovative solutions for neurodegenerative diseases.
